ALLIANCE
LABORATORIES

PREVENTIVE COGNITIVE WELLNESS

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

CLIA Certified

WELCOME TO **ALLIANCE™**

At ALLIANCE™ Laboratories, we prioritize quality and technology to ensure the highest standards in diagnostic testing. Our commitment to quality begins with our state-of-the-art laboratory facilities equipped with the latest advancements in diagnostic technology.

ALLIANCE™ Laboratories offers a comprehensive range of advanced diagnostic services:

- **Clinical Testing**
- **Pathology Testing**
- **Molecular Testing**
- **Toxicology Testing**
- **Genetic Testing**

By integrating advanced technology with stringent quality control measures, ALLIANCE™ Laboratories delivers exceptional accuracy and reliability in every test we perform. We are dedicated to advancing healthcare through innovation, ensuring that patients receive the highest level of care and service.

INSURANCE LIST

INSURANCES OUR LABORATORY ACCEPTS

1199 National Benefit Fund
AARO - Prudential
Aetna HMO
Aetna PPO
AliCare
All Union Local Insurances
Amalgamated
American Plan Administrators
American Progressive Life (Today's Options)
AmeriHealth PPO
APWU
AvMed
BayCare
Blue Cross Blue Shield
Brokerage Concepts
Capital District (CDPHP)
Capital Health Plan
Care Plus
Champ VA
Christian Brothers Employee Benefit Fund
Cigna HMO
Cigna PPO
ConnectiCare
CoreSource
Emblem Health
Empire Plan (United Healthcare)
Fidelis
Florida Blue
GEHA
GHI
Great West Health Care PPO
Harvard Pilgrim Healthcare
Elderplan
HCPIPA (Healthcare Partners)
Health First
Health Republic (Freelancers)
HIP
Hudson Health Plan
Humana
Horizaon BCBS
Liberty Health Advantage
Local Unions
MagnaCare
Mail Handlers Benefit Plan
Medicare
Medicaid
Meritain Health
MetroPlusHealth Plan
Multiplan
MVP Healthcare
NALC Health Benefit
Oscar Health Insurance
Oxford HMO
Oxford PPO
Preferred Care
POMCO
QualCare
Railroad Medicare
Senior Whole Health
Sieba Ltd
Touchstone
Tricare
TRPN
UniCare PPO
United Healthcare
(Excluding Community Plan)
United Healthcare/
AARP Medicare Complete Advantage

INSURANCES WE DO NOT ACCEPT

Affinity
Amerigroup
CMO
Health Plus
Northshore LIJ
United Healthcare Community Plan

WATCH **CMS.GOV**
VIDEO HERE

DOES YOUR PRACTICE PROVIDE COGNITIVE TESTING?

(CPT Code: 99483)

As healthcare providers, you are constantly seeking ways to improve patient care and outcomes. One significant yet often underutilized approach is cognitive testing. This preventive approach can play a crucial role in early identification of brain health issues, such as dementia, which in turn can significantly benefit patients and their families.
To learn more about integrating these services into your practice, visit Medicare Cognitive Assessment & Care Plan Services webpage CMS.gov: **http://cms.gov/cognitive**





WHY CHOOSE ALLIANCE™ LABORATORIES?

- EXPERT TEAM
- FAST TURNAROUND
- STATE-OF-THE-ART TECHNOLOGY

ALLIANCE™ Laboratories offer advanced Cognitive Testing Panels that enhance CMS Cognitive Assessment & Care Plan Services, providing a comprehensive picture of patients' cognitive health. By integrating our **(2646) Initial Cognitive Panel** and in 6-month **(2647) Follow-Up Cognitive Panel** testing, you can identify cognitive impairments early, tailor individualized care plans, and monitor progress effectively.

ALLIANCE™ **KNOWLEDGE**

Learn more about conducting an initial patient visit:

Patient #1

Patient #2

Learn more about conducting a follow-up patient visit:

ALLIANCE LABORATORIES

PATIENT INFORMATION (REQUIRED)

Last Name: _____ First Name: _____

Street Address: _____ Apt#: _____

City: _____ State: _____ Zip: _____

Phone: _____ DOB: ___/___/_____ SSN: _____ Gender: F ☐ M ☐

Primary Ethnicity: ☐ African ☐ European (Finnish) ☐ Latino
☐ Ashkenazi Jewish ☐ East Asian ☐ South Asian
☐ European (Non-Finnish) ☐ Near/Middle Eastern ☐ Other

SPECIMEN INFORMATION (REQUIRED)

Date Collected: ___/___/_____ Time Collected : _____

Collected and Registered By: _____

ICD10 CODES

It is the ordering party's responsibility to order only those tests medically necessary for the diagnosis and treatment of the patient.

☐ 2646 - Initial Cognitive Profile (3SSP;2KV1RBL;1SAL)

CBC w/DIFF	Progesterone
Cortisol A.M.	Renel Functon Panel
DHEA-S	Reverse T3, Serum
Estradiol	SHBG
Ferritin	T4 Total
Folate	Testosterone, Free
FT3	Testosterone, Total
FT4	Total T3
GGT	TSH
Heavy Metals 18	Uric Acid, Serum
Hemoglobin A1C	Vitamin B12
High Sensitivity CRP	Vitamin D 25-OH
Homocysteine	Vitamin E, Serum
Insulin	
LDH	
Lipid Profile w/rflx LDL Direct	
PGX Comprehensive Panel	

☐ 2647 - Follow Up Cognitive Panel (3SST;1LV1RBL)

CBC w/DIFF	Progesterone
Cortisol A.M.	Renel Functon Panel
DHEA-S	Reverse T3, Serum
Estradiol	SHBG
Ferritin	T4 Total
Folate	Testosterone, Free
FT3	Testosterone, Total
FT4	Total T3
GGT	TSH
Heavy Metals 18	Uric Acid, Serum
Hemoglobin A1C	Vitamin B12
High Sensitivity CRP	Vitamin D 25-OH
Homocysteine	
Insulin	
LDH	
Lipid Profile w/rflx LDL Direct	

BLOOD ICD 10

☐ E78.2	Mixed hyperlipidemia	☐ E53.8	Def of other specified B Group vitamins	☐ R53.1	Weakness
☐ E11.9	Type 2 diabetes mellitus without complications	☐ E55.9	Vitamin D deficiency, unspecified	☐ R79.9	Ab. finding of blood chemistry, unspecified
☐ E03.9	Unspecified Hypothyroidism	☐ E72.11	Homocystinuria	☐ R53.81	Other malaise
☐ I10.0	Essential Primary Hypertension	☐ E78.01	Familial hypercholesterolemia	☐ R79.89	Other specified abnormal findings of blood chemistry
☐ D64.9	Anemia, unspecified	☐ E78.1	Pure hyperglyceridemia	☐ Z79.01	Long term (current) use of anticoagulants
☐ R73.09	Other abnormal Glucose	☐ E78.49	Other hyperlipidemia	☐ Z79.899	Other long term (current) drug therapy
☐ E73.03	Abnormal Glucose, Prediabetes	☐ I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris		
☐ D51.9	Vitamin B12 deficiency anemia, unspecified				

PGX ICD10

COLUMN 1* (SELECT ALL THAT MAY APPLY):

☐ I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	☐ I25.791	Atherosclerotic of other coronary artery bypass grafts with angina pectoris with documented spasm
☐ I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	☐ I25.798	Atherosclerotic of other coronary artery bypass grafts with other forms of angina pectoris
☐ I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	☐ I25.810	Atherosclerotic of coronary artery bypass grafts without angina pectoris
☐ I25.5	Ischemic cardiomyopathy	☐ I25.812	Atherosclerotic of bypass grafts of coronary artery of transplanted heart without angina pectoris
☐ I25.6	Silent myocardial ischemia	☐ I25.83	Coronary atherosclerosis due to lipid rich plaque
☐ I25.720	Atherosclerotic of autologous artery coronary artery bypass grafts with unstable angina pectoris	☐ I25.84	Coronary atherosclerosis due to calcified coronary lesion
☐ I25.721	Atherosclerotic of autologous artery coronary artery bypass grafts with angina pectoris with documented spasm	☐ I25.89	Other forms of chronic ischemic heart disease
☐ I25.728	Atherosclerotic of autologous artery coronary artery bypass grafts with other forms of angina pectoris	☐ I25.9	Chronic ischemic heart disease, unspecified
☐ I25.760	Atherosclerotic of bypass graft of coronary artery of transplanted heart with unstable angina	☐ I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery
☐ I25.761	Atherosclerotic of bypass graft of coronary artery of transplanted heart with angina pectoris w/documented spasm	☐ I66.01	Occlusion and stenosis of right middle cerebral artery
☐ I25.768	Atherosclerotic of bypass of coronary artery of transplanted heart with other forms of pectoris	☐ I66.02	Occlusion and stenosis of left middle cerebral artery
☐ I25.790	Atherosclerotic of other coronary artery bypass grafts with unstable angina pectoris	☐ I66.03	Occlusion and stenosis of bilateral middle cerebral arteries
		☐ I66.8	Occlusion and stenosis of other cerebral arteries
		☐ Z79.02	Long term (current) use of antithrombotics/ antiplatelets

COLUMN 2* (SELECT ALL THAT MAY APPLY):

☐ F33.40	Major depressive disorder, recurrent in remission, unspecified	☐ F31.61	Bipolar disorder, current episode mixed, mild
☐ F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	☐ F31.62	Bipolar disorder, current episode mixed, moderate
☐ F32.9	Major depressive disorder, single episode, unspecified	☐ F31.63	Bipolar disorder, current episode mixed, severe, w/o psychotic features
☐ F33.9	Major depressive disorder, recurrent, unspecified	☐ F31.77	Bipolar disorder, in partial remission, most recent episode mixed
☐ F33.0	Major depressive disorder, recurrent, mild	☐ F31.78	Bipolar disorder, in full remission, most recent episode mixed
☐ F33.1	Major depressive disorder, recurrent, moderate	☐ F32.89	Other specified depressive episodes
☐ F33.2	Major depressive disorder, recurrent, severe without psychotic features	☐ F31.64	Bipolar disorder, current episode mixed, severe, w/ psychotic features
☐ F33.41	Major depressive disorder, recurrent, in partial remission	☐ F31.5	Bipolar disorder, current episode depressed, severe with psychotic features
☐ F33.42	Major depressive disorder, recurrent, in full remission	☐ G10	Huntington's disease
☐ F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified		
☐ F31.31	Bipolar disorder, current episode depressed, mild		
☐ F31.32	Bipolar disorder, current episode depressed, moderate		
☐ F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features		
☐ F31.75	Bipolar disorder, in partial remission, most recent episode mixed depressed		
☐ F31.76	Bipolar disorder, in full remission, most recent episode depressed		
☐ F31.60	Bipolar disorder, current episode mixed, unspecified		

Medical Necessity (Please check one or more boxes):

- ☐ Patient has acute coronary syndrome and is undergoing percutaneous coronary interventions, and needs genetic testing of the CYP2C19 to guide the initiation or re-initiation of **Clopidogrel (Plavix)** therapy, or any medication derivatives.
- ☐ Patient has a depressive disorder and needs genetic testing of the CYP2D to guide medical treatment of the patient and/or dosing of **amitriptyline** or **nortriptyline**, or any medication derivatives.
- ☐ Patient needs genetic testing of CYP2D6 to guide initial dosing or re-initiation of **Tetrabenzine**, at a rate greater than 50 mg/day, or any medication derivatives.
- ☐ Patient (1) has not been previously tested for the CYP2C9 or VKORC1 alleles, (2) has received fewer than (5) days' warfarin in the anticoagulation treatment plan for which the genetic testing is requested, and (3) the patients enrolled in a prospective, randomized, controlled study meeting Medicare requirements under NCD90.1.
- ☐ The patient had an adverse reaction to one or more drug combinations and is currently taking the following medications. Please list below:

_____

PHYSICIAN SIGNATURE _____

022-PGX-03/20

***Note: The provided ICD-10 codes are listed as a convenience. Ordering practitioners should report the diagnosis code that best describes the reason for performing the test, regardless of whether the code is listed above or not.**

00001

00001

* FPO Affixed Label

TO RE-ORDER CALL RITE-PRINT 714.828.4283



ALLIANCE LABORATORIES

3611 14TH AVE SUITE 102
BROOKLYN, NY 11218-3750
Tel. (718)851-5773 Fax (718)851-3919
Laboratory Director: Samar Roy, PhD
CLIA#: 33D0985206

Client: [redacted] 2394
Phys: [redacted] Fax: [redacted]

Patient: [redacted]
DOB. [redacted] Age: 83 Sex: F
Phone: [redacted] ID#: [redacted]

Accession:2301030408	Coll. Date: 01/03/23	Recv. Date: 01/03/23	Print Date: 07/04/24
Chart#	Coll. Time: 11:00	Recv. Time: 20:09	Print Time: 09:32
First reported on:	01/04/23	Final report date:	07/04/24

Clinical Report:

Clinical Abnormalities Summary: (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.)

GLUCOSE	162	mg/dL	HIGH	74.0 - 106.0
B.U.N.	24.0	mg/dL	HIGH	9.00 - 23.00
BUN/CREATININE RATIO	39	RATIO	HIGH	8 - 28
ALK.PHOSPHATASE	41	U/L	LOW	46.0 - 116.0
GLYCOHEMOGLOBIN A1C	6.9	%	HIGH	4.00 - 5.69
CRP HIGH SENSITIVITY	0.89	mg/L	LOW	1.0 - 3.0
HOMOCYSTEINE	10.01	umol/L	HIGH	3.70 - 13.90
HDL CHOLESTEROL	42	mg/dL	LOW	>=60
TRIGLYCERIDES	153	mg/dL		
RBC	3.59	10^6/u		
HGB	11.0	g/dL		
HCT	32.5	%		
MCV	90.6	fL		
MPV	11.3	fL		
SEGMENTED %	78.3	%		
FOLATE	3.58	ng/mL		
VITAMIN D 25-OH	25.1	ng/mL		
INSULIN	30.5	uIU/mL		

Test Name	Within Range	Out
CHEMISTRY		
GLUCOSE		162 H
SODIUM	143	
POTASSIUM	3.9	
CHLORIDE	107	
BICARBONATE	25	
CREATININE	0.61	
GLOMERULAR FILTRATION	94	
If African-American, result is: >		
B.U.N.		24.0
BUN/CREATININE RATIO		39 H
CALCIUM	9.2	
T.PROTEIN	6.6	
ALBUMIN	4.3	
GLOBULIN	2.3	
A/G RATIO	1.87	
ALK.PHOSPHATASE		41 L
URIC ACID	5.2	
LACTATE DEHYDROGENASE	201	
BILIRUBIN,Total	0.5	
BILIRUBIN,Direct	0.20	
GGT	15	
SGPT (ALT)	21	

(Continued on Next P

CLS PGx Research Review

CORIELL LIFE SCIENCES

Coriell Life Sciences
4747 S. Broad St., Suite 222 • Philadelphia, PA
Phone: (888) 415-7834
www.coriell.com/

Presented here are the results of the Coriell Life Sciences systematic review of available guidance and research literature. The CLS PGx Research Review is a general purpose research assistance service intended to provide users with relevant medical reference information related to identified gene variations and their drug associations. This research review reflects the professional opinions of the CLS research team, and are intended solely for general purpose research use and are not intended for use in clinical diagnosis or treatment. Independent review of the same evidence can be performed, with referenced sources documented at coriell.com/refs.

Patient:
Date of Birth:

Sample ID: 2402098002

Table of Contents

Genetic Research Summary Information

† Key: Indeterminant, Uncertain = No known diplotype or activity; Negative = wild type alleles; Positive = heterozygous or homozygous alleles; n/a = no gene information available.

Genetic Research Summary

Gene	Diplotype	Activity †
ApoE	E3|E3	See ApoE Research Summary
COMT(Val158Met)	G|A	Decreased function
CYP1A2	*1N|*1W	Unknown Metabolizer
CYP2B6	*1|*1	Normal metabolizer
CYP2C19	*1|*2	Intermediate metabolizer
CYP2C9	*1|*1	Normal metabolizer
CYP2D6	*2A|*2B; or *2A|*2A; or *2B|*2B	Normal metabolizer
CYP3A4	*1A|*1A	Normal metabolizer
CYP3A5	*1|*3	Intermediate metabolizer
Factor V Leiden	Normal	See Thrombosis Research Summary
MTHFR (A1298C)	T|G	See Thrombosis Research Summary
MTHFR (C677T)	G|G	See Thrombosis Research Summary
Prothrombin (F2)	Normal	See Thrombosis Research Summary
SLCO1B1	*1|*1	Normal function
VKORC1	*1|*1	Low sensitivity to warfarin

ALLIANCE
LABORATORIES

CONTACT US

NORTHEAST

3611 14TH AVE, SUITE 102
BROOKLYN, NY 11218

(718) 851-5773

support@alliancelab.com

SOUTHEAST

7200 W CAMINO REAL, SUITE 330
BOCA RATON, FL 33433

(561) 453-1234

clientsupport@alliancelab.com

alliancelaboratories.com